Garamycin (Gentamicin Sulfate): Clinical Monograph, Dosing & Safety

Garamycin® (Gentamicin Sulfate)

1. Disclaimer

This medication profile is provided for professional and educational reference only and does not constitute medical advice, diagnosis, or treatment recommendation. It is not a substitute for the current approved product information, antimicrobial susceptibility results, clinical judgment, or individualized prescribing by a qualified healthcare professional. Gentamicin is a prescription-only, potentially nephrotoxic and ototoxic aminoglycoside that requires careful dose selection, renal-function assessment, and therapeutic drug monitoring whenever feasible when used systemically.

We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.

2. Summary

Garamycin® is a brand of gentamicin sulfate, a bactericidal aminoglycoside antibiotic, marketed in Egypt by Memphis Pharmaceutical & Chemical Industries in several dosage forms: parenteral ampoules (20 mg/2 mL, 40 mg/1 mL, and 80 mg/2 mL) for intramuscular or intravenous use, and topical dermatological presentations (0.1% cream in 15 g and 30 g tubes, 0.1% ointment in 15 g, and Garamycin Plus cream 30 g).

The injectable forms are indicated for serious infections caused by susceptible organisms, mainly aerobic Gram-negative bacilli and susceptible staphylococci; because of the narrow therapeutic margin of systemic gentamicin, treatment must be guided by body weight, renal function, infection severity, and — whenever feasible — serum-concentration monitoring. The topical forms are intended for susceptible bacterial skin infections and produce minimal systemic exposure under normal use, though the class cautions (hypersensitivity, superinfection, avoidance of prolonged widespread application) still apply.

3. Brand Name

Garamycin® — available in the Egyptian market in the following presentations:

Presentation	Dosage form
Garamycin 20 mg/2 mL	Ampoules for injection (pack of 6)
Garamycin 40 mg/1 mL (40 mg/mL)	Ampoules for injection (pack of 6)
Garamycin 80 mg/2 mL (40 mg/mL)	Ampoules for injection (pack of 3)
Garamycin 0.1% cream	Topical cream, 15 g and 30 g tubes
Garamycin 0.1% ointment	Topical ointment, 15 g tube
Garamycin Plus cream	Topical combination cream, 30 g tube

The brand was originally associated with Schering-Plough; the active antibiotic in all core presentations is gentamicin. For the exact composition of the combination "Plus" cream, the current package leaflet should be consulted. This profile focuses on the parenteral injection, with the topical presentations addressed where clinically relevant.

4. Category

• Therapeutic category: Antibacterial (antibiotic).
• Pharmacological class: Aminoglycoside.
• ATC classification: J01GB03 (gentamicin, systemic); D06AX07 (gentamicin, topical dermatological).

The injectable form is a sterile systemic aminoglycoside for serious aerobic Gram-negative infections; the topical forms are for local treatment of susceptible skin infections.

5. Active Ingredient

Gentamicin sulfate, equivalent to gentamicin base:

• Injection: 40 mg gentamicin base per mL in the 40 mg/1 mL and 80 mg/2 mL ampoules; 10 mg/mL in the 20 mg/2 mL ampoule.
• Topical cream/ointment: gentamicin (as sulfate) 0.1% w/w.

Gentamicin is a mixture of the C1, C1a, and C2 components, produced by Micromonospora purpurea.

Injection excipients include methylparaben, propylparaben, sodium metabisulfite, disodium edetate, and water for injection. Sodium metabisulfite is clinically relevant because sulfites may cause hypersensitivity-type reactions, including bronchospasm, in susceptible individuals. Each ampoule contains a very small amount of sodium (less than 1 mmol / 23 mg per ampoule).

6. Pharmaceutical Form & Strength

A) Injectable (sterile aqueous solution in type-I glass ampoules, for IM injection and IV injection/infusion after dilution):

Presentation	Strength	Pack
Garamycin 20 mg/2 mL	10 mg gentamicin base per mL	6 ampoules
Garamycin 40 mg/1 mL	40 mg gentamicin base per mL	6 ampoules
Garamycin 80 mg/2 mL	40 mg gentamicin base per mL	3 ampoules

B) Topical dermatological:

Presentation	Strength	Pack
Garamycin cream	0.1% w/w gentamicin	15 g and 30 g tubes
Garamycin ointment	0.1% w/w gentamicin	15 g tube
Garamycin Plus cream	Combination (see local leaflet)	30 g tube

Availability and pack sizes may change; the locally supplied pack and leaflet take precedence.

7. Manufacturer & Marketing Authorization Holder

Manufacturer: Memphis Company for Pharmaceutical & Chemical Industries (Memphis Pharmaceuticals), Cairo, Egypt — historically produced under the authority of Schering-Plough Corporation (USA). The publicly available Egyptian product information does not separately designate a distinct legal entity as "Marketing Authorization Holder"; Memphis is identified as the responsible manufacturer for the full Garamycin line (injections, cream, ointment, and Plus cream), and the local registration record or package leaflet should be consulted for the formal MAH.

8. Mechanism of Action

Gentamicin is actively transported into susceptible bacterial cells by an oxygen-dependent process and binds primarily to the 30S ribosomal subunit, inhibiting protein synthesis, causing misreading of mRNA with production of abnormal proteins, and affecting plasma-membrane integrity — resulting in bactericidal activity. Systemically, its killing is concentration-dependent with a clinically important post-antibiotic effect, providing the pharmacodynamic rationale for once-daily/extended-interval dosing of the injection in appropriate patients.

9. Spectrum of Activity

Clinically useful activity is principally against susceptible aerobic Gram-negative bacilli:

Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia spp., Proteus spp. (indole-positive and indole-negative), Providencia spp., and Pseudomonas aeruginosa.

It is also active against susceptible Staphylococcus species (coagulase-positive and coagulase-negative, including some penicillin- and methicillin-resistant strains) — relevant to the topical treatment of staphylococcal skin infections.

Important limitations:

• Most streptococci and enterococci are poor targets for aminoglycoside monotherapy, although gentamicin may act synergistically with a cell-wall–active agent (e.g., penicillin G, ampicillin) against susceptible enterococci in selected serious infections such as endocarditis; synergy with carbenicillin against P. aeruginosa is also documented.
• No useful activity against anaerobes (e.g., Bacteroides, Clostridium), because uptake is oxygen-dependent.
• Despite in-vitro activity against Salmonella and Shigella, aminoglycosides are not clinically effective against infections caused by these organisms; in-vitro susceptibility results for them should not be reported.
• Resistance develops (aminoglycoside-modifying enzymes, altered uptake, target modification); cross-resistance among aminoglycosides may occur, though gentamicin may retain activity against isolates resistant to other aminoglycosides. Topical overuse may promote resistant skin flora — culture and susceptibility testing should guide therapy whenever feasible.

10. Pharmacokinetics

Systemic (injection):

• Absorption: poorly absorbed from the gastrointestinal tract. After IM injection, peak serum concentrations occur within approximately 30–60 minutes and remain measurable for 6–8 hours; a two-hour IV infusion gives similar concentrations.
• Distribution: mainly extracellular fluid; volume of distribution approximately 0.25–0.3 L/kg in typical adults, and larger per kg in the young — about 0.5–0.7 L/kg in premature neonates, falling toward adult values with age. Plasma protein binding is low (0–30%). Concentrates in the renal cortex (up to ~8× serum); crosses the placenta; CSF penetration is low and variable even with meningeal inflammation; minimal ocular penetration.
• Metabolism: no clinically significant metabolic transformation.
• Elimination: excreted largely unchanged by glomerular filtration (renal clearance similar to creatinine clearance); ≥70% of a dose is recoverable in urine within 24 hours with normal renal function. Half-life approximately 2–3 hours with normal renal function; markedly prolonged in renal impairment and in neonates (averaging ~8 hours at 26–34 weeks' gestation and ~6.7 hours at 35–37 weeks). Small tissue-bound amounts may be detectable in urine for weeks after discontinuation. Probenecid does not affect its tubular transport.

Topical (cream/ointment):

systemic absorption through intact skin is minimal; appreciable absorption — and potential systemic toxicity — can occur with application to large areas, broken or inflamed skin, or prolonged use, particularly in renal impairment.

11. Indications

A) Injection — serious infections caused by susceptible strains of Pseudomonas aeruginosa, Proteus spp., E. coli, the Klebsiella–Enterobacter–Serratia group, Citrobacter spp., and Staphylococcus spp., including:

• Bacterial neonatal sepsis and septicemia/bacteremia
• Serious CNS infections, including meningitis (as part of an appropriate regimen)
• Serious urinary tract infections
• Serious respiratory tract infections
• Gastrointestinal/intra-abdominal infections, including peritonitis
• Skin, bone, and soft-tissue infections, including infected burns and wounds

It may be used as initial empiric therapy in suspected serious Gram-negative infection — often combined with a penicillin- or cephalosporin-type agent when Gram-positive or anaerobic coverage is also needed — pending susceptibility results.

B) Topical cream/ointment — local treatment of primary and secondary bacterial skin infections caused by susceptible organisms (e.g., impetigo, infected eczema, infected wounds or burns, folliculitis). Topical use should be short-term and confined to the affected area; it is not a substitute for systemic therapy in deep or spreading infection.

Key qualifications:

• Use only when a susceptible bacterial infection is proven or strongly suspected, to limit resistance.
• The injection is not indicated for uncomplicated initial urinary-tract infections unless the organism is susceptible and less-toxic alternatives are unsuitable.
• Gonorrhea: gentamicin is not first-line; current CDC guidance recommends ceftriaxone 500 mg IM once (1 g if ≥150 kg). A gentamicin 240 mg IM single dose plus azithromycin 2 g orally regimen is an alternative specifically for patients with cephalosporin allergy. Gentamicin is cautioned in pregnancy.

12. Administration

A) Injection (IM or IV):

dose based on (ideal) body weight, renal function, severity, and — whenever feasible — serum gentamicin concentrations. If serum concentrations cannot be monitored, prescribing gentamicin is not recommended.

• Adults with normal renal function: 3–5 mg/kg/day depending on severity, as a single daily dose (preferred) or in two divided doses; a frequency above twice daily may be adopted for certain pathogens or infection sites per local guidance. Once-daily dosing should be given by the IV route and is not recommended in endocarditis. For urinary-tract infections in patients with normal renal function, 160 mg once daily may be used. (Traditional labeling: 3 mg/kg/day in three divided doses, up to 5 mg/kg/day in life-threatening infection, reduced as soon as clinically indicated.)
• Pediatric patients (current product information): children ≥1 year and adolescents: 3–6 mg/kg/day as a single daily dose (preferred) or two divided doses; infants after the first month of life: 4.5–7.5 mg/kg/day; neonates and pre-term infants (0–4 weeks): 4–7 mg/kg/day given once daily because of the longer half-life. (Traditional US schedules: children 6–7.5 mg/kg/day q8h; infants/neonates >1 week 7.5 mg/kg/day q8h; neonates ≤1 week 5 mg/kg/day q12h.)
• Renal impairment: decrease the daily dose and/or extend the interval with frequent peak/trough and renal monitoring; no clear recommendation exists for once-daily dosing in renal impairment — let levels guide. In moderate impairment where once-daily dosing would otherwise apply, the interval should be at least 24 hours and extended per monitoring. When assays are unavailable, the interval (hours) may be approximated by multiplying serum creatinine (mg/100 mL) by 8.
• Hemodialysis: an 8-hour dialysis removes approximately 50% of the drug; a post-dialysis dose of about 1–1.7 mg/kg (children 2 mg/kg) is used depending on severity, guided by levels. Peritoneal dialysis removes the drug far less efficiently.
• Duration: usually 7–10 days; keep therapy as short as compatible with clinical recovery, since toxicity is exposure-related.
• Therapeutic drug monitoring: pre-dose trough levels should not exceed 1 mg/L (once-daily) or 2 mg/L (multiple-daily); excess indicates the need to extend the interval, not reduce the dose. Post-dose peak levels (measured 1 hour after an IM/IV bolus, or 30 minutes after the end of an infusion) below 4 mg/L suggest underdosing, while levels above 10 mg/L indicate increased toxicity risk — avoid prolonged concentrations above 12 mcg/mL.
• Obesity: dose on ideal body weight with close serum-level monitoring; dose reduction may be considered in significant obesity.

B) Topical cream/ointment:

apply a thin layer to the affected area, usually 2–3 times daily, for the shortest effective duration. Do not apply to large areas, deep wounds, or extensively broken skin, and avoid occlusive dressings unless directed by a physician.

13. Method of Preparation

Injection: a ready-to-use sterile solution — no reconstitution required. Do not use unless the solution is clear and the container undamaged.

• IM: inject the prescribed dose directly.
• IV: inject slowly directly into a vein or drip-set tubing over no less than 3 minutes, or dilute and infuse over 20–30 minutes in no more than 100 mL of sterile 0.9% sodium chloride or 5% dextrose (longer infusions up to 60 minutes may be used, particularly for once-daily regimens). Use the diluted preparation within 2 hours.
• Do not physically premix gentamicin with beta-lactam antibiotics in the same solution — in-vitro inactivation occurs (clinically most relevant in severe renal impairment); administer separately by different routes.

Topical forms: ready to use. Clean and dry the affected area before application; wash hands before and after.

14. Contraindications

Injection:

• Known hypersensitivity to gentamicin or any formulation component (including sulfites/parabens).
• History of serious hypersensitivity or serious toxic reaction to another aminoglycoside (cross-sensitivity).
• Myasthenia gravis (aminoglycosides aggravate neuromuscular transmission disorders).

Topical forms:

• Hypersensitivity to gentamicin, other aminoglycosides, or any excipient.
• Not for ophthalmic use; avoid application where systemic absorption could be substantial (extensive burns or denuded skin) unless specifically justified.

15. Warnings & Precautions

Systemic (injection):

• Nephrotoxicity: risk rises with renal impairment, high doses, prolonged therapy, dehydration, and advanced age. Monitor urine (specific gravity, protein, cells, casts), BUN, serum creatinine, and creatinine clearance before and during therapy; evidence of toxicity requires dose adjustment or discontinuation, and changes may appear only after therapy ends.
• Ototoxicity: vestibular (dizziness, vertigo, imbalance) and cochlear (tinnitus, high-tone hearing loss) toxicity may be irreversible; obtain serial audiograms when feasible, especially in high-risk patients.
• Mitochondrial variants: ototoxicity has occurred with MT-RNR1 variants (particularly m.1555A>G) even at recommended serum levels; consider alternatives with a maternal family history of aminoglycoside deafness or a known variant.
• Neuromuscular blockade: rare blockade and respiratory paralysis, especially with anesthetics, neuromuscular blockers (succinylcholine, tubocurarine, decamethonium), or massive citrate-anticoagulated transfusions; intravenous calcium salts may reverse the blockade. Use caution in myasthenia gravis, parkinsonism, and other states of muscular weakness.
• Sodium metabisulfite: allergic-type reactions, including anaphylaxis and life-threatening asthmatic episodes in susceptible individuals (more frequent in asthmatics).
• Electrolyte disturbances: hypomagnesemia (notably with prolonged therapy), hypocalcemia, and hypokalemia with paresthesias, tetany, and positive Chvostek/Trousseau signs; a Fanconi-like syndrome with aminoaciduria and metabolic acidosis has been reported.
• Maintain adequate hydration; watch for overgrowth of nonsusceptible organisms; neurotoxic/nephrotoxic antibiotics can be absorbed from body surfaces after irrigation or topical surgical application.

Topical:

• Prolonged or extensive use may cause sensitization, local irritation, and overgrowth of nonsusceptible organisms including fungi; discontinue if these occur.
• Systemic absorption from large, broken, or inflamed areas — especially with renal impairment — may rarely reach clinically relevant concentrations; use the smallest amount for the shortest duration.

16. Drug Interactions

• Other nephrotoxic agents (vancomycin, amphotericin B, cisplatin, ciclosporin, polymyxin B, colistin, cephalosporins — particularly cephaloridine — and other aminoglycosides): additive renal toxicity; avoid concurrent or sequential use where possible, or monitor renal function closely.
• Potent diuretics (furosemide, ethacrynic acid): increased ototoxicity risk — avoid concurrent use.
• Other aminoglycosides: generally avoided (additive toxicity); cross-allergenicity within the class is demonstrated.
• Neuromuscular-blocking agents and anesthetics: potentiated blockade, risk of respiratory paralysis.
• Beta-lactams: clinically useful synergy in selected infections, but physical mixing in the same solution causes inactivation; reduced gentamicin half-life has been reported with concomitant carbenicillin in severe renal impairment — administer separately.
• Indomethacin: may raise gentamicin plasma concentrations in neonates.
• Oral anticoagulants: possible increased hypoprothrombinemic effect.
• Bisphosphonates: increased risk of hypocalcemia.
• Botulinum toxin: increased toxicity risk via enhanced neuromuscular blockade.
• Neostigmine / pyridostigmine: antagonism of their effect may occur with concomitant gentamicin.

Clinically significant interactions are essentially a concern of systemic therapy; topical use at recommended extent and duration is unlikely to produce relevant systemic interactions, though caution applies with widespread application in renal impairment.

17. Side Effects

Systemic (injection):

• Nephrotoxicity: urinary casts/cells/protein, rising BUN and creatinine, oliguria; usually reversible; very rarely acute renal failure or Fanconi-like syndrome with prolonged high-dose courses.
• Ototoxicity/neurotoxicity: dizziness, vertigo, tinnitus, transient or irreversible hearing loss, vestibular damage (particularly after ototoxic-drug exposure or renal dysfunction); peripheral neuropathy, numbness, muscle twitching, encephalopathy, convulsions; rarely respiratory depression.
• Hypersensitivity: rash, pruritus, urticaria, purpura, anaphylaxis including anaphylactic shock; very rarely Stevens–Johnson syndrome/toxic epidermal necrolysis.
• Other: vomiting (very common), nausea, stomatitis, antibiotic-associated colitis, headache, fever, lethargy, confusion, depression, hallucinations, hypotension or hypertension, visual disturbances, weight loss, alopecia, joint pain.
• Laboratory: increased transaminases, LDH, bilirubin; decreased calcium, magnesium, sodium, potassium; anemia, leukopenia, granulocytopenia, thrombocytopenia, eosinophilia.
• Local: injection-site pain; rarely subcutaneous atrophy or fat necrosis.

Topical:

local irritation, redness, itching, and allergic contact dermatitis; prolonged use risks fungal or resistant-bacterial superinfection. Systemic aminoglycoside toxicity is a remote possibility only with heavy use over large or broken skin areas, especially in renal impairment.

18. Use in Special Populations

• Pregnancy: systemic gentamicin crosses the placenta; aminoglycosides can cause fetal harm, and total irreversible bilateral congenital deafness has been reported with class use in pregnancy. Use the injection only in life-threatening situations where expected benefit outweighs the risk, and apprise the patient of the hazard. Topical use produces minimal absorption but should still be limited to clear need on small areas.
• Breastfeeding: amounts ingested from milk are unlikely to produce significant infant blood levels in the absence of infant gastrointestinal inflammation; weigh the drug's importance to the mother.
• Neonates/premature infants: larger extracellular-water compartment and immature renal function prolong elimination (half-life up to ~8 hours in the most premature) — individualize dose and interval and monitor serum concentrations.
• Children: weight- and age-dependent dosing per the current pediatric schedules; do not apply adult schedules directly.
• Elderly: renal function may be reduced despite a "normal" serum creatinine — creatinine clearance is more useful; monitor levels, renal function, and signs of ototoxicity closely.
• Renal impairment: dose reduction and/or interval extension with frequent monitoring (injection); caution with extensive topical application.
• Obesity: dose on ideal body weight with level monitoring; consider dose reduction in significant obesity.
• Burn patients: half-life may be significantly decreased with lower-than-expected serum concentrations after systemic dosing — monitoring recommended; extensive topical application to burns also increases absorption.

19. Storage Conditions

Injection: store at a temperature not exceeding 30°C per the current product information (products in some other markets are labeled for USP controlled room temperature, 20–25°C, protected from light, not frozen — the local pack leaflet takes precedence). Do not use if the solution is discolored or contains particles; once diluted for IV infusion with saline or 5% dextrose, use within 2 hours.

Cream/ointment: store per the local pack (typically not exceeding 30°C) in the original tightly closed tube, away from light and out of reach of children; do not use after the printed expiry date.

20. Additional Sections

• Overdose: no specific antidote; supportive management with assessment of renal function and serum concentration. Hemodialysis aids removal (especially with impaired renal function); peritoneal dialysis is considerably less efficient; exchange transfusion may be considered in neonates. Intravenous calcium salts have been used to counter gentamicin-induced neuromuscular blockade.
• Monitoring: baseline and serial renal function, serum gentamicin peak/trough concentrations (mandatory in the elderly, newborns, obesity, renal impairment, cystic fibrosis), assessment for tinnitus/hearing loss/vertigo/imbalance and neuromuscular weakness, plus electrolytes and hematology during prolonged therapy.
• Antimicrobial stewardship/resistance: prescribing without a proven or strongly suspected bacterial infection is unlikely to benefit and increases resistance — applying equally to unnecessary topical antibiotic use; antibacterial drugs do not treat viral infections, and the full prescribed course should be completed.
• Current therapeutic role: gentamicin injection remains valuable for selected serious or resistant Gram-negative infections (including certain resistant urinary pathogens per contemporary infectious-diseases guidance) when susceptibility is demonstrated, with duration kept short because nephrotoxicity is exposure-dependent; topical gentamicin remains an option for localized susceptible skin infections where local resistance patterns permit.

21. Frequently Asked Questions (FAQ)

Q1. In which forms is Garamycin available?

As ampoules for injection — 20 mg/2 mL (pack of 6), 40 mg/1 mL (pack of 6), and 80 mg/2 mL (pack of 3) — and as topical products: 0.1% cream (15 g and 30 g), 0.1% ointment (15 g), and Garamycin Plus cream (30 g).

Q2. Is Garamycin injection the same as gentamicin injection?

Yes — it contains gentamicin sulfate equivalent to gentamicin base.

Q3. Is Garamycin a broad-spectrum antibiotic?

Broad within the aminoglycoside class — mainly susceptible aerobic Gram-negative bacilli and staphylococci — but not universal: no useful activity against anaerobes and most streptococci/enterococci.

Q4. Can the injection be given intravenously?

Yes — IM or IV (slow injection over ≥3 minutes or diluted infusion); note that once-daily regimens should be given by the IV route.

Q5. Does the injection need reconstitution?

No — ready-to-use sterile solution; only dilution in saline or 5% dextrose for IV infusion, used within 2 hours.

Q6. What are the cream and ointment used for?

Localized susceptible bacterial skin infections; the cream is generally preferred for weeping lesions and the ointment for dry lesions. Use short courses on limited areas.

Q7. Can gentamicin damage the kidneys?

Yes — nephrotoxicity is a principal toxicity of systemic use; risk rises with renal impairment, excessive exposure, dehydration, and prolonged treatment.

Q8. Can it cause permanent hearing loss?

Yes — cochlear and vestibular toxicity may be irreversible and may appear only after therapy ends.

Q9. Why are blood levels monitored?

Because of the narrow therapeutic margin: troughs above 1–2 mg/L (regimen-dependent) and peaks above 10–12 mg/L increase toxicity, while peaks below 4 mg/L may be inadequate. If levels cannot be monitored, prescribing is discouraged.

Q10. Can the injection be used for a simple urinary-tract infection?

Generally not preferred when an effective, less-toxic alternative exists; reserved for selected serious or resistant infections (a 160 mg once-daily regimen is described for UTI when renal function is normal and use is justified).

Q11. Is it a first-line treatment for gonorrhea?

No — ceftriaxone 500 mg IM once is first-line; gentamicin 240 mg IM plus azithromycin 2 g is an alternative specifically for cephalosporin allergy.

Q12. Can it be used during pregnancy?

Systemically, only in life-threatening situations where benefit outweighs the fetal ototoxicity risk; topical use should be limited to clear need on small areas.

Q13. Can the injection be mixed with a penicillin in the same infusion?

No — physical mixing inactivates gentamicin; give the agents separately by different routes.

Q14. Can the injection be given once daily?

Yes — once-daily dosing (3–5 mg/kg/day, IV route) is the preferred regimen for appropriate patients with normal renal function, with monitoring; it is not recommended in endocarditis and is not clearly recommended in renal impairment.

Q15. What is the single most important safety consideration?

For systemic use: balancing efficacy against nephrotoxicity and ototoxicity through individualized dosing, renal-function assessment, and serum-concentration monitoring. For topical use: avoiding prolonged or extensive application to prevent sensitization, resistance, and absorption.

22. References

1. Memphis Pharmaceutical & Chemical Industries Co. — Garamycin 40 mg/1 mL and 80 mg/2 mL Ampoules — Product Information (official product pages; also the source of the topical Garamycin line listings): https://www.memphis.com.eg/Products/Details/33 ; https://www.memphis.com.eg/Products/Details/32 [10]
2. DailyMed / U.S. National Library of Medicine — Gentamicin Sulfate Injection, USP — current prescribing information (boxed warning, clinical pharmacology, microbiology, dosage, monitoring, adverse reactions): https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5113bfad-42ca-4bb8-9343-0b08c6cd03f0
3. Centers for Disease Control and Prevention (CDC) — Sexually Transmitted Infections Treatment Guidelines — Gonococcal Infections Among Adolescents and Adults: https://www.cdc.gov/std/treatment-guidelines/gonorrhea-adults.htm
4. Infectious Diseases Society of America (IDSA) — Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: https://www.idsociety.org/practice-guideline/amr-guidance/